APVO
Aptevo Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$6.17M
P/E Ratio
0.00
EPS
$1488.13
Beta
1.65
52W High
$100.59
52W Low
$3.80
50-Day MA
$4.73
200-Day MA
$16.59
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
3.89
PEG Ratio
0.00
About Aptevo Therapeutics Inc
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 345,000 |
| EBITDA | $-26.45M |
| Operating Margin | 0.00% |
| Return on Equity | -518.00% |
| Return on Assets | -118.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $9.65 |
| Price-to-Book | 0.53 |
| Price-to-Sales (TTM) | 2.70 |
| EV/Revenue | 0.0011 |
| EV/EBITDA | 0.39 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $1.25M |
| Float | $1.25M |
| % Insiders | 0.06% |
| % Institutions | 4.46% |
Historical Volatility
HV 10-Day
63.75%
HV 20-Day
66.37%
HV 30-Day
68.35%
HV 60-Day
88.90%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($21.00 target)
1
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026